NKTR
HealthcareNektar Therapeutics
$72.86+2.50 (+3.55%)
Prev Close
$70.36
Open
$72.64
High
$77.00
Low
$70.00
Volume
1.14M
Market Cap
$1.41B
P/E
—
Div Yield
—
Over the past 12 months, insider activity at Nektar Therapeutics (NKTR) has been exclusively selling, with 0 insider purchases totaling $0.00 and 19 insider sales totaling $1.41M. The most recent insider transaction was by ROBIN HOWARD W (director, officer: President & CEO), who sold $30.9K worth of shares on Feb 20, 2026. Nektar Therapeutics operates in the Healthcare sector, within the Biotechnology industry, with a market cap of $1.41B.
Buys (12M)
0
$0.00
Sells (12M)
19
$1.41M
Net Activity
Net Seller
$1.41M
Active Insiders
3
last 12 mo
NKTR Price Chart
NKTR Insider Trading Activity
| Date | Insider | Role | Type | Shares | Avg Price | Value | Shares After |
|---|---|---|---|---|---|---|---|
| Feb 20, 2026↗ | ROBIN HOWARD W | director, officer: President & CEO | Sell | 423 | $73.00 | $30.9K | 75,489 |
| Feb 20, 2026↗ | Zalevsky Jonathan | officer: Chief R&D Officer | Sell | 180 | $73.00 | $13.1K | 21,174 |
| Feb 18, 2026↗ | ROBIN HOWARD W | President & CEO | Sell | 423 | $73.00 | $30.9K | 0 |
| Feb 18, 2026↗ | Zalevsky Jonathan | Chief R&D Officer | Sell | 180 | $73.00 | $13.1K | 0 |
| Jan 22, 2026↗ | Zalevsky Jonathan | officer: Chief R&D Officer | Sell | 3,867 | $35.67 | $137.9K | 21,354 |
| Nov 25, 2025↗ | ROBIN HOWARD W | President & CEO | Sell | 2,207 | $54.28 | $119.8K | 54,245 |
| Nov 25, 2025↗ | Wilson Mark Andrew | Chief Legal Officer | Sell | 630 | $54.28 | $34.2K | 21,585 |
| Nov 25, 2025↗ | Zalevsky Jonathan | Chief R&D Officer | Sell | 1,157 | $54.28 | $62.8K | 18,971 |
| Sep 11, 2025↗ | ROBIN HOWARD W | President & CEO | Sell | 6,666 | $46.69 | $311.2K | 53,908 |
| Sep 8, 2025↗ | ROBIN HOWARD W | President & CEO | Sell | 11,832 | $36.42 | $431.0K | 65,917 |
| Sep 8, 2025↗ | Zalevsky Jonathan | Chief R&D Officer | Sell | 1,721 | $33.52 | $57.7K | 18,390 |
| Sep 4, 2025↗ | ROBIN HOWARD W | President & CEO | Sell | 1,500 | $30.16 | $45.2K | 67,840 |
| Sep 4, 2025↗ | Zalevsky Jonathan | Chief R&D Officer | Sell | 485 | $30.10 | $14.6K | 19,183 |
| Aug 21, 2025↗ | ROBIN HOWARD W | President & CEO | Sell | 1,573 | $26.59 | $41.8K | 69,340 |
| Aug 21, 2025↗ | Wilson Mark Andrew | Chief Legal Officer | Sell | 676 | $26.59 | $18.0K | 20,312 |
| Aug 21, 2025↗ | Zalevsky Jonathan | Chief R&D Officer | Sell | 725 | $26.59 | $19.3K | 19,668 |
| May 21, 2025↗ | ROBIN HOWARD W | President & CEO | Sell | 23,208 | $0.67 | $15.5K | 1,063,690 |
| May 21, 2025↗ | Wilson Mark Andrew | Chief Legal Officer | Sell | 9,996 | $0.67 | $6.7K | 314,296 |
| May 21, 2025↗ | Zalevsky Jonathan | Chief R&D Officer | Sell | 10,712 | $0.67 | $7.2K | 305,892 |
| Feb 21, 2025↗ | ROBIN HOWARD W | President & CEO | Sell | 23,774 | $1.01 | $24.0K | 1,086,900 |
| Feb 21, 2025↗ | Wilson Mark Andrew | Chief Legal Officer | Sell | 11,040 | $1.01 | $11.2K | 324,292 |
| Feb 21, 2025↗ | Zalevsky Jonathan | Chief R&D Officer | Sell | 10,300 | $1.01 | $10.4K | 316,604 |
| Dec 26, 2024↗ | Wilson Mark Andrew | Chief Legal Officer | Sell | 49,962 | $0.90 | $44.8K | 351,892 |
| Dec 20, 2024↗ | Zalevsky Jonathan | Chief R&D Officer | Sell | 51,115 | $0.94 | $48.0K | 326,904 |
| Dec 19, 2024↗ | ROBIN HOWARD W | President & CEO | Sell | 132,030 | $1.00 | $131.7K | 1,195,710 |
| Nov 20, 2024↗ | ROBIN HOWARD W | President & CEO | Sell | 16,278 | $1.01 | $16.4K | 832,080 |
| Nov 20, 2024↗ | Wilson Mark Andrew | Chief Legal Officer | Sell | 6,407 | $1.01 | $6.5K | 218,856 |
| Nov 20, 2024↗ | Zalevsky Jonathan | Chief R&D Officer | Sell | 7,785 | $1.01 | $7.9K | 243,019 |
| Aug 20, 2024↗ | ROBIN HOWARD W | President & CEO | Sell | 14,881 | $1.28 | $19.0K | 848,358 |
| Aug 20, 2024↗ | Wilson Mark Andrew | Chief Legal Officer | Sell | 5,651 | $1.28 | $7.2K | 225,263 |
| Aug 20, 2024↗ | Zalevsky Jonathan | Chief R&D Officer | Sell | 6,866 | $1.28 | $8.8K | 250,804 |
| Jun 14, 2024↗ | CHESS ROBERT | Sell | 19,500 | $1.20 | $23.4K | 255,273 | |
| May 20, 2024↗ | ROBIN HOWARD W | President & CEO | Sell | 16,650 | $1.75 | $29.1K | 863,239 |
| May 20, 2024↗ | Wilson Mark Andrew | Chief Legal Officer | Sell | 6,260 | $1.75 | $11.0K | 230,414 |
| May 20, 2024↗ | Zalevsky Jonathan | Chief R&D Officer | Sell | 7,355 | $1.75 | $12.9K | 257,670 |
| May 13, 2024↗ | Deep Track Capital, LP | Sell | 56,000 | $1.78 | $99.6K | 18,344,000 | |
| Feb 22, 2024↗ | ROBIN HOWARD W | President & CEO | Sell | 20,033 | $0.68 | $13.6K | 879,889 |
| Feb 22, 2024↗ | Wilson Mark Andrew | Chief Legal Officer | Sell | 7,606 | $0.68 | $5.2K | 236,674 |
| Feb 22, 2024↗ | Zalevsky Jonathan | Chief R&D Officer | Sell | 9,014 | $0.68 | $6.1K | 265,025 |
| Nov 20, 2023↗ | ROBIN HOWARD W | President & CEO | Sell | 19,877 | $0.49 | $9.7K | 899,922 |
| Nov 20, 2023↗ | Wilson Mark Andrew | Chief Legal Officer | Sell | 7,179 | $0.49 | $3.5K | 243,780 |
| Nov 20, 2023↗ | Zalevsky Jonathan | Chief R&D Officer | Sell | 9,646 | $0.49 | $4.7K | 274,039 |
| Sep 20, 2023↗ | Ajer Jeffrey Robert | Director | Sell | 4,359 | $0.69 | $3.0K | 34,153 |
| Sep 20, 2023↗ | CHESS ROBERT | Director | Sell | 10,200 | $0.67 | $6.8K | 274,773 |
| Sep 20, 2023↗ | Curet Myriam | Director | Sell | 4,359 | $0.69 | $3.0K | 27,418 |
| Aug 17, 2023↗ | ROBIN HOWARD W | President & CEO | Sell | 19,998 | $0.78 | $15.6K | 919,799 |
| Aug 17, 2023↗ | Wilson Mark Andrew | Chief Legal Officer | Sell | 7,221 | $0.78 | $5.6K | 250,959 |
| Aug 17, 2023↗ | Zalevsky Jonathan | Chief R&D Officer | Sell | 9,703 | $0.78 | $7.6K | 283,685 |
| Jun 15, 2023↗ | WHITFIELD ROY A | Director | Sell | 30,000 | $0.57 | $17.1K | 216,250 |
| May 17, 2023↗ | ROBIN HOWARD W | President & CEO | Sell | 20,361 | $0.72 | $14.7K | 939,797 |
Showing 1–50 of 106
1 / 3
NKTR Insider Buying Activity
The following table shows recent insider purchases of Nektar Therapeutics (NKTR) stock reported via SEC Form 4 filings.
No insider buying activity found for NKTR in the last 12 months.
NKTR Insider Selling Activity
The following table shows recent insider sales of Nektar Therapeutics (NKTR) stock reported via SEC Form 4 filings.
| Date | Insider | Role | Type | Shares | Avg Price | Value | Shares After |
|---|---|---|---|---|---|---|---|
| Feb 20, 2026↗ | ROBIN HOWARD W | director, officer: President & CEO | Sell | 423 | $73.00 | $30.9K | 75,489 |
| Feb 20, 2026↗ | Zalevsky Jonathan | officer: Chief R&D Officer | Sell | 180 | $73.00 | $13.1K | 21,174 |
| Feb 18, 2026↗ | ROBIN HOWARD W | President & CEO | Sell | 423 | $73.00 | $30.9K | 0 |
| Feb 18, 2026↗ | Zalevsky Jonathan | Chief R&D Officer | Sell | 180 | $73.00 | $13.1K | 0 |
| Jan 22, 2026↗ | Zalevsky Jonathan | officer: Chief R&D Officer | Sell | 3,867 | $35.67 | $137.9K | 21,354 |
| Nov 25, 2025↗ | ROBIN HOWARD W | President & CEO | Sell | 2,207 | $54.28 | $119.8K | 54,245 |
| Nov 25, 2025↗ | Wilson Mark Andrew | Chief Legal Officer | Sell | 630 | $54.28 | $34.2K | 21,585 |
| Nov 25, 2025↗ | Zalevsky Jonathan | Chief R&D Officer | Sell | 1,157 | $54.28 | $62.8K | 18,971 |
| Sep 11, 2025↗ | ROBIN HOWARD W | President & CEO | Sell | 6,666 | $46.69 | $311.2K | 53,908 |
| Sep 8, 2025↗ | ROBIN HOWARD W | President & CEO | Sell | 11,832 | $36.42 | $431.0K | 65,917 |
| Sep 8, 2025↗ | Zalevsky Jonathan | Chief R&D Officer | Sell | 1,721 | $33.52 | $57.7K | 18,390 |
| Sep 4, 2025↗ | ROBIN HOWARD W | President & CEO | Sell | 1,500 | $30.16 | $45.2K | 67,840 |
| Sep 4, 2025↗ | Zalevsky Jonathan | Chief R&D Officer | Sell | 485 | $30.10 | $14.6K | 19,183 |
| Aug 21, 2025↗ | ROBIN HOWARD W | President & CEO | Sell | 1,573 | $26.59 | $41.8K | 69,340 |
| Aug 21, 2025↗ | Wilson Mark Andrew | Chief Legal Officer | Sell | 676 | $26.59 | $18.0K | 20,312 |
| Aug 21, 2025↗ | Zalevsky Jonathan | Chief R&D Officer | Sell | 725 | $26.59 | $19.3K | 19,668 |
| May 21, 2025↗ | ROBIN HOWARD W | President & CEO | Sell | 23,208 | $0.67 | $15.5K | 1,063,690 |
| May 21, 2025↗ | Wilson Mark Andrew | Chief Legal Officer | Sell | 9,996 | $0.67 | $6.7K | 314,296 |
| May 21, 2025↗ | Zalevsky Jonathan | Chief R&D Officer | Sell | 10,712 | $0.67 | $7.2K | 305,892 |
| Feb 21, 2025↗ | ROBIN HOWARD W | President & CEO | Sell | 23,774 | $1.01 | $24.0K | 1,086,900 |
| Feb 21, 2025↗ | Wilson Mark Andrew | Chief Legal Officer | Sell | 11,040 | $1.01 | $11.2K | 324,292 |
| Feb 21, 2025↗ | Zalevsky Jonathan | Chief R&D Officer | Sell | 10,300 | $1.01 | $10.4K | 316,604 |
| Dec 26, 2024↗ | Wilson Mark Andrew | Chief Legal Officer | Sell | 49,962 | $0.90 | $44.8K | 351,892 |
| Dec 20, 2024↗ | Zalevsky Jonathan | Chief R&D Officer | Sell | 51,115 | $0.94 | $48.0K | 326,904 |
| Dec 19, 2024↗ | ROBIN HOWARD W | President & CEO | Sell | 132,030 | $1.00 | $131.7K | 1,195,710 |
| Nov 20, 2024↗ | ROBIN HOWARD W | President & CEO | Sell | 16,278 | $1.01 | $16.4K | 832,080 |
| Nov 20, 2024↗ | Wilson Mark Andrew | Chief Legal Officer | Sell | 6,407 | $1.01 | $6.5K | 218,856 |
| Nov 20, 2024↗ | Zalevsky Jonathan | Chief R&D Officer | Sell | 7,785 | $1.01 | $7.9K | 243,019 |
| Aug 20, 2024↗ | ROBIN HOWARD W | President & CEO | Sell | 14,881 | $1.28 | $19.0K | 848,358 |
| Aug 20, 2024↗ | Wilson Mark Andrew | Chief Legal Officer | Sell | 5,651 | $1.28 | $7.2K | 225,263 |
| Aug 20, 2024↗ | Zalevsky Jonathan | Chief R&D Officer | Sell | 6,866 | $1.28 | $8.8K | 250,804 |
| Jun 14, 2024↗ | CHESS ROBERT | Sell | 19,500 | $1.20 | $23.4K | 255,273 | |
| May 20, 2024↗ | ROBIN HOWARD W | President & CEO | Sell | 16,650 | $1.75 | $29.1K | 863,239 |
| May 20, 2024↗ | Wilson Mark Andrew | Chief Legal Officer | Sell | 6,260 | $1.75 | $11.0K | 230,414 |
| May 20, 2024↗ | Zalevsky Jonathan | Chief R&D Officer | Sell | 7,355 | $1.75 | $12.9K | 257,670 |
| May 13, 2024↗ | Deep Track Capital, LP | Sell | 56,000 | $1.78 | $99.6K | 18,344,000 | |
| Feb 22, 2024↗ | ROBIN HOWARD W | President & CEO | Sell | 20,033 | $0.68 | $13.6K | 879,889 |
| Feb 22, 2024↗ | Wilson Mark Andrew | Chief Legal Officer | Sell | 7,606 | $0.68 | $5.2K | 236,674 |
| Feb 22, 2024↗ | Zalevsky Jonathan | Chief R&D Officer | Sell | 9,014 | $0.68 | $6.1K | 265,025 |
| Nov 20, 2023↗ | ROBIN HOWARD W | President & CEO | Sell | 19,877 | $0.49 | $9.7K | 899,922 |
| Nov 20, 2023↗ | Wilson Mark Andrew | Chief Legal Officer | Sell | 7,179 | $0.49 | $3.5K | 243,780 |
| Nov 20, 2023↗ | Zalevsky Jonathan | Chief R&D Officer | Sell | 9,646 | $0.49 | $4.7K | 274,039 |
| Sep 20, 2023↗ | Ajer Jeffrey Robert | Director | Sell | 4,359 | $0.69 | $3.0K | 34,153 |
| Sep 20, 2023↗ | CHESS ROBERT | Director | Sell | 10,200 | $0.67 | $6.8K | 274,773 |
| Sep 20, 2023↗ | Curet Myriam | Director | Sell | 4,359 | $0.69 | $3.0K | 27,418 |
| Aug 17, 2023↗ | ROBIN HOWARD W | President & CEO | Sell | 19,998 | $0.78 | $15.6K | 919,799 |
| Aug 17, 2023↗ | Wilson Mark Andrew | Chief Legal Officer | Sell | 7,221 | $0.78 | $5.6K | 250,959 |
| Aug 17, 2023↗ | Zalevsky Jonathan | Chief R&D Officer | Sell | 9,703 | $0.78 | $7.6K | 283,685 |
| Jun 15, 2023↗ | WHITFIELD ROY A | Director | Sell | 30,000 | $0.57 | $17.1K | 216,250 |
| May 17, 2023↗ | ROBIN HOWARD W | President & CEO | Sell | 20,361 | $0.72 | $14.7K | 939,797 |
NKTR Insiders
Similar Stocks to NKTR
VRTX
Vertex Pharmaceuticals Incorporated
$470.20-1.66%
$121.44B
REGN
Regeneron Pharmaceuticals, Inc.
$743.51-0.41%
$77.57B
ALNY
Alnylam Pharmaceuticals, Inc.
$313.45-1.19%
$42.07B
INSM
Insmed Incorporated
$139.06-0.33%
$30.07B
UTHR
United Therapeutics Corporation
$536.12+0.97%
$23.50B
MRNA
Moderna, Inc.
$52.56-1.89%
$20.76B
ROIV
Roivant Sciences Ltd.
$28.06-1.44%
$20.08B
RPRX
Royalty Pharma plc
$45.65-0.57%
$19.56B